A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Dyadic International Inc stock. As of the latest transaction made, Citadel Advisors LLC holds 20,600 shares of DYAI stock, worth $23,277. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,600
Previous 11,400 80.7%
Holding current value
$23,277
Previous $16,000 31.25%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.04 - $1.55 $2,149 - $3,203
2,067 Added 35.37%
7,911 $8,000
Q2 2024

Aug 14, 2024

SELL
$1.39 - $2.27 $5,151 - $8,412
-3,706 Reduced 38.81%
5,844 $8,000
Q1 2024

May 15, 2024

SELL
$1.29 - $1.67 $44,943 - $58,182
-34,840 Reduced 78.49%
9,550 $15,000
Q4 2023

Feb 14, 2024

BUY
$1.52 - $2.04 $18,308 - $24,571
12,045 Added 37.24%
44,390 $71,000
Q3 2023

Nov 14, 2023

SELL
$1.71 - $2.08 $53,104 - $64,594
-31,055 Reduced 48.98%
32,345 $62,000
Q2 2023

Aug 14, 2023

BUY
$1.56 - $2.38 $47,945 - $73,146
30,734 Added 94.09%
63,400 $122,000
Q1 2023

May 15, 2023

BUY
$1.25 - $1.86 $3,228 - $4,804
2,583 Added 8.59%
32,666 $58,000
Q4 2022

Feb 14, 2023

SELL
$1.18 - $2.32 $3,547 - $6,973
-3,006 Reduced 9.08%
30,083 $37,000
Q3 2022

Nov 14, 2022

SELL
$1.65 - $3.42 $30,221 - $62,640
-18,316 Reduced 35.63%
33,089 $63,000
Q2 2022

Aug 15, 2022

BUY
$1.85 - $3.22 $68,157 - $118,631
36,842 Added 252.98%
51,405 $157,000
Q1 2022

May 16, 2022

SELL
$3.01 - $4.81 $11,820 - $18,888
-3,927 Reduced 21.24%
14,563 $44,000
Q3 2021

Nov 15, 2021

BUY
$3.3 - $6.49 $458 - $902
139 Added 0.76%
18,490 $103,000
Q4 2020

Feb 16, 2021

BUY
$5.35 - $7.77 $98,177 - $142,587
18,351 New
18,351 $99,000

Others Institutions Holding DYAI

About DYADIC INTERNATIONAL INC


  • Ticker DYAI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,423,100
  • Market Cap $32.1M
  • Description
  • Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vac...
More about DYAI
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.